Eris Lifesciences Announces Quarterly Results for June 30, 2026; Confirms Cost Auditor Re-appointment
Eris Lifesciences Limited reported its unaudited consolidated and standalone financial results for the quarter ended June 30, 2026. The Board of Directors reviewed and approved these financial statements during a meeting held on July 29, 2026.In addition to the operational review, the Board also took note of the re-appointment of M/s Kiran J. Mehta & Co., Cost Accountants, as the Cost Auditors of the Company for the financial year 2026-27. M/s Kiran J. Mehta & Co. is a partnership firm established in 1990, having originated as a proprietorship concern by Late Shri Kirankumar J. Mehta in 1977.
Consolidated Financial Performance
The consolidated results for the quarter ending June 30, 2026, reflect various operational aspects across the Group's subsidiaries and joint ventures. The total income for the quarter stood at 875.64 crore, derived from a Total Revenue from operations of 873.25 crore.The company maintained a Net worth of 3,944.22 crore as of June 30, 2026. Key ratios tracked during the quarter included a Debt to Equity Ratio of 0.64 times and a Current Ratio of 0.60 times. The net profit for the period was recorded at 143.32 crore.
Standalone Results Highlight Stability and Growth
The standalone unaudited financial results for Eris Lifesciences Limited for the same quarter demonstrated a robust operating profile. Total income stood at 470.37 crore, driven by total revenue from operations of 443.99 crore.The company's balance sheet showed Net Worth amounting to 3,148.45 crore as of June 30, 2026. The operational metrics for the quarter included a Debt to Equity Ratio of 0.62 times and an Operating Margin of 23.94%. The period saw a net profit of 48.30 crore.
Key Financial Metrics Summary (Rs in Crore)
A summary of key financial indicators across the two reporting categories for the quarter ending June 30, 2026:| Metric | Consolidated Results | Standalone Results |
|---|---|---|
| Total Income | 875.64 | 470.37 |
| Net Worth | 3,944.22 | 3,148.45 |
| Debt to Equity Ratio | 0.64 times | 0.62 times |
| Net Profit after Tax | 143.32 | 48.30 |
The company is primarily engaged in the "Pharmaceuticals" business segment, as determined by the chief operating decision maker. The Board of Directors also noted that the company declared an interim dividend of Rs 7.21/- per equity share for the financial year 2026-27.
ERIS Stock Price Movement
Shares of Eris Lifesciences Limited are edging higher to ₹1414 as of 2:26 PM, gaining 1.67% in live trading. The equity maintains significant momentum amid brisk activity, with 211,197 shares traded and the stock oscillating within an intraday range defined by a low of ₹1383.9 and a high of ₹1421.1.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.